^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    RAD54L (DNA Repair And Recombination Protein RAD54)

    i
    Other names: RAD54L, DNA Repair And Recombination Protein RAD54, RAD54 Homolog, RAD54A, HRAD54, HHR54, RAD54 Like (S. Cerevisiae), RAD54 (S.Cerevisiae)-Like
    3d
    NIRADO: Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (clinicaltrials.gov)
    P2, N=51, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Dec 2027 --> Feb 2025 | Suspended --> Terminated; Abandon of the partner, GSK
    Trial completion date • Trial termination • Pan tumor • Platinum sensitive
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • ARID2 (AT-Rich Interaction Domain 2) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)
    |
    HER-2 positive • HER-2 amplification • DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    4d
    ARIANES: Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (clinicaltrials.gov)
    P2, N=130, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | Suspended --> Terminated; Bankruptcy of partner: Clovis
    Trial termination • Pan tumor • Platinum sensitive
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • IL2 (Interleukin 2) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)
    |
    DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Tecentriq (atezolizumab) • Rubraca (rucaparib)
    1m
    A Case of Metastatic Castration-Resistant Prostate Cancer With RAD54L Mutation Responding to Niraparib. (PubMed, IJU Case Rep)
    Niraparib was effective for mCRPC with RAD54L gene mutation. The prospective trial of patient-proposed healthcare services with multiple targeted agents based on the results of gene profiling by multigene panel test (BELIEVE) (NCCH1901/jRCTs031190104).
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • RAD54L (DNA Repair And Recombination Protein RAD54)
    |
    RAD54L mutation
    |
    FoundationOne® CDx
    |
    Zejula (niraparib)
    2ms
    Exome sequencing reveals new insights into the germline landscape of inflammatory breast cancer among Tunisian patients. (PubMed, J Transl Med)
    Our findings revealed a complex and heterogeneous genetic background of IBC in the Tunisian population that might contribute to disease susceptibility and impact disease prognosis. The genetic features of IBC presented in this study provide valuable insights into the molecular mechanisms underlying the disease offering not only a deeper understanding within the context of Tunisia but also shedding light on its relevance to other North African populations characterized by similar epidemiological and genetic features.
    Journal • BRCA Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • MTHFR (Methylenetetrahydrofolate Reductase) • RAD54L (DNA Repair And Recombination Protein RAD54) • XRCC2 (X-Ray Repair Cross Complementing 2) • IFNAR2 (Interferon Alpha And Beta Receptor Subunit 2) • ABRAXAS1 (Abraxas 1 BRCA1 A Complex Subunit 2)
    |
    RAD54L mutation
    2ms
    Comparative bioinformatics analysis of the Wnt pathway in breast cancer: Selection of novel biomarker panels associated with ER status. (PubMed, Open Life Sci)
    Thus, this study revealed potential diagnostic and prognostic signatures based on comprehensive analyses of BC patient data sourced from The Cancer Genome Atlas database. Consequently, four gene signatures were constructed: two differentiate ER+ from ER-BC: TTC8, SLC5A7, and PLCH1 for overall survival (OS); ZNF695, SLC7A5, and PLCH1 for disease free survival (DFS), while the other two effectively distinguish tumor from normal samples: SPC25, ANLN, KPNA2, SLC7A5 for OS; SPC25, KIF20A, SKA3, DTL, CDCA3, ANLN, TTK, RAD54L, MYBL2, ZNF695, and SLC7A5 for DFS.
    Journal
    |
    CDCA3 (Cell Division Cycle Associated 3) • RAD54L (DNA Repair And Recombination Protein RAD54) • SLC7A5 (Solute Carrier Family 7 Member 5) • MYBL2 (MYB Proto-Oncogene Like 2) • ANLN (Anillin Actin Binding Protein) • KIF20A (Kinesin Family Member 20A) • KPNA2 (Karyopherin Subunit Alpha 2)
    2ms
    Integrated analysis and experimental validation of E2F2 as a potential prognostic biomarker and its oncogenic roles in serous ovarian cancer. (PubMed, Front Mol Biosci)
    It may serve as a potential biomarker for diagnosis, patient stratification, and guiding personalized therapy. Further research could enhance SOC management.
    Journal • IO biomarker
    |
    CD4 (CD4 Molecule) • RAD54L (DNA Repair And Recombination Protein RAD54) • CCNF (Cyclin F) • E2F2 (E2F Transcription Factor 2) • ORC1 (Origin Recognition Complex Subunit 1)
    3ms
    Genetic Variants Associated with Breast Cancer Are Detected by Whole-Exome Sequencing in Vietnamese Patients. (PubMed, Diagnostics (Basel))
    This is the first WES study to identify BC-associated genetic variants in Vietnamese patients, providing a comprehensive database of BC susceptibility gene variants. We suggest using WES as a tool to identify genetic variants in BC patients for risk prediction and treatment guidance.
    Journal
    |
    ER (Estrogen receptor) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • NF1 (Neurofibromin 1) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • PMS2 (PMS1 protein homolog 2) • MSH3 (MutS Homolog 3) • BARD1 (BRCA1 Associated RING Domain 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • CASP8 (Caspase 8) • WRN (WRN RecQ Like Helicase) • CHD8 (Chromodomain Helicase DNA Binding Protein 8) • RECQL (RecQ Like Helicase) • KLLN (Killin P53 Regulated DNA Replication Inhibitor) • LZTR1 (Leucine Zipper Like Transcription Regulator 1) • RB1CC1 (RB1 Inducible Coiled-Coil 1) • SLX4 (SLX4 Structure-Specific Endonuclease Subunit) • XRCC3 (X-Ray Repair Cross Complementing 3) • ACVR1B (Activin A Receptor Type 1B)
    3ms
    Niraparib in Tumors Metastatic to the CNS (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BAP1 (BRCA1 Associated Protein 1) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • XRCC2 (X-Ray Repair Cross Complementing 2) • RAD54B (RAD54 Homolog B) • XRCC3 (X-Ray Repair Cross Complementing 3)
    |
    HRD • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation
    |
    Zejula (niraparib)
    3ms
    Contributions of DNA double strand break repair pathways to DNA crosslink repair. (PubMed, DNA Repair (Amst))
    We show that DNA-PKcs-deficient mES cells are resistant to the crosslinkers mitomycin C (MMC), cisplatin and carboplatin, contrasting with the increased sensitivity observed in mES cells lacking Rad54. In clinical settings, higher PRKDC expression correlates with poorer survival, while elevated RAD54L and POLQ expression correlates with better survival in cisplatin-treated cervical and head and neck cancers. These findings reflect the opposing roles of NHEJ versus HR and TMEJ in replication-associated DSB repair, as observed in vitro.
    Journal
    |
    RAD54L (DNA Repair And Recombination Protein RAD54) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)
    |
    cisplatin • carboplatin • mitomycin
    3ms
    Construction and Validation of a Novel Prognostic Model Based on Cervical Cancer-Related Genes. (PubMed, Reprod Sci)
    APOD is a prognostic biomarker for cervical cancer, and the prognostic model constructed by identified cervical cancer-related genes can successfully distinguish the prognosis of patients with cervical cancer.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • RAD54L (DNA Repair And Recombination Protein RAD54) • FOXM1 (Forkhead Box M1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • MYBL2 (MYB Proto-Oncogene Like 2) • CDC45 (Cell Division Cycle 45) • CEP55 (Centrosomal Protein 55) • KIF4A (Kinesin Family Member 4A) • MCM2 (Minichromosome maintenance complex component 2) • MCM5 (Minichromosome Maintenance Complex Component 5) • RFC4 (Replication Factor C Subunit 4) • DNA2 (DNA Replication Helicase/Nuclease 2) • SPAG5 (Sperm Associated Antigen 5)
    3ms
    Clinicopathological features of Chinese ovarian cancer patients with double heterozygosity for cancer-predisposed genes. (PubMed, BMC Cancer)
    Our study suggests that BRCA1 variant seems to drive the phenotypic expressions of ovarian cancer patients with DH. The management of these patients might be like BRCA1-mutated patients. Harboring DH may further increase the family member's chance of acquiring cancer of various types.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RAD51C (RAD51 paralog C) • RAD54L (DNA Repair And Recombination Protein RAD54) • MUTYH (MutY homolog) • RECQL4( RecQ Like Helicase 4)
    4ms
    BRACeD: Carboplatin or Olaparib for BRcA Deficient Prostate Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, VA Office of Research and Development | Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Aug 2025 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    RAD51B (RAD51 Paralog B) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • RAD54L (DNA Repair And Recombination Protein RAD54)
    |
    RAD54L mutation
    |
    Lynparza (olaparib) • carboplatin